For example, the rise in tAkt is of potential interest because it could inhibit GSK‐3β, a major tau phosphorylation regulator implicated in Alzheimer's disease progression (Takashima, 2006). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.